NxStage Medical, Inc. (NASDAQ:NXTM) – Investment analysts at William Blair cut their Q4 2017 earnings per share estimates for shares of NxStage Medical in a research note issued on Thursday. William Blair analyst M. Kaczor now expects that the medical device company will earn $0.02 per share for the quarter, down from their prior estimate of $0.03. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for NxStage Medical’s Q3 2018 earnings at $0.02 EPS, Q4 2018 earnings at $0.04 EPS and FY2018 earnings at $0.10 EPS.
Several other research firms have also commented on NXTM. Jefferies Group LLC lowered shares of NxStage Medical from a “buy” rating to a “hold” rating and lowered their price target for the stock from $33.00 to $30.00 in a research report on Tuesday. Stephens lowered shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $33.00 to $30.00 in a research report on Wednesday. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Thursday. BTIG Research lowered shares of NxStage Medical from a “buy” rating to a “neutral” rating in a research report on Friday. Finally, Northland Securities lowered shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 4th. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $30.29.
TRADEMARK VIOLATION WARNING: This report was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/08/12/nxstage-medical-inc-nxtm-forecasted-to-post-q4-2017-earnings-of-0-02-per-share.html.
NxStage Medical (NASDAQ:NXTM) opened at 29.22 on Friday. The stock’s market capitalization is $1.93 billion. The firm’s 50-day moving average is $24.92 and its 200 day moving average is $25.85. NxStage Medical has a 12 month low of $20.45 and a 12 month high of $30.80.
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The company had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same period last year, the firm posted ($0.03) EPS. NxStage Medical’s revenue for the quarter was up .0% on a year-over-year basis.
A number of large investors have recently bought and sold shares of NXTM. BlackRock Inc. increased its stake in NxStage Medical by 38,360.4% in the first quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after buying an additional 4,401,851 shares during the last quarter. FMR LLC increased its stake in NxStage Medical by 31.8% in the second quarter. FMR LLC now owns 9,860,278 shares of the medical device company’s stock valued at $247,197,000 after buying an additional 2,378,077 shares during the last quarter. Eagle Asset Management Inc. bought a new stake in NxStage Medical during the first quarter valued at $54,558,000. William Blair Investment Management LLC increased its stake in NxStage Medical by 491.6% in the second quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock valued at $49,120,000 after buying an additional 1,628,114 shares during the last quarter. Finally, Loomis Sayles & Co. L P increased its stake in NxStage Medical by 365.9% in the first quarter. Loomis Sayles & Co. L P now owns 708,946 shares of the medical device company’s stock valued at $19,021,000 after buying an additional 556,780 shares during the last quarter. 91.11% of the stock is owned by institutional investors and hedge funds.
In related news, President Joseph E. Turk, Jr. sold 24,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $29.64, for a total value of $711,360.00. Following the completion of the sale, the president now owns 82,903 shares of the company’s stock, valued at $2,457,244.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total transaction of $25,190.00. Following the completion of the sale, the president now directly owns 75,903 shares of the company’s stock, valued at approximately $1,911,996.57. The disclosure for this sale can be found here. Insiders sold 53,900 shares of company stock valued at $1,404,073 in the last ninety days. Corporate insiders own 4.70% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.